G
Gordon B. Magill
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 44
Citations - 1945
Gordon B. Magill is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Chemotherapy & Sarcoma. The author has an hindex of 17, co-authored 44 publications receiving 1899 citations.
Papers
More filters
Journal ArticleDOI
Malignant schwannoma--clinical characteristics, survival, and response to therapy.
Peter P. Sordillo,Peter P. Sordillo,Lawrence Helson,Steven I. Hajdu,Gordon B. Magill,Cynthia Kosloff,Robert B. Golbey,Edward J. Beattie +7 more
TL;DR: Malignant schwannoma should be considered in the differential diagnosis of tumors developing in areas previously treated with radiation, as well as in the clinical course of both groups of patients, although local recurrence had a more ominous prognosis in patients with neurofibromatosis.
Journal ArticleDOI
Extraosseous osteogenic sarcoma: A review of 48 patients
TL;DR: The clinical records and histologic material of 48 patients with extraosseous osteogenic sarcoma were reviewed, and the course of most patients was that of multiple local recurrences followed by pulmonary metastases and death, with median survivals greater than 60 months for patients receiving these treatments.
Journal ArticleDOI
Malignant mesothelioma of the pleura: review of 123 patients.
TL;DR: Except for nine patients, tumor was confined to the chest at the time of diagnosis, but in 33 of the remaining 114 patients, spread to the abdomen or distant metastasis was seen during the course of disease, so surgery and radiotherapy were ineffective in preventing local recurrence.
Journal ArticleDOI
Local Recurrence in Adult Soft-Tissue Sarcoma: A Randomized Trial of Brachytherapy
Murray F. Brennan,Basil S. Hilaris,Man H. Shiu,Joseph M. Lane,Gordon B. Magill,Claudia Friedrich,Steven I. Hajdu +6 more
TL;DR: The benefit of adjuvant radiation therapy delivered by the brachytherapy technique in 117 adult patients who had soft-tissue sarcoma that was on an extremity or superficially localized to the trunk and a significant decrease in local recurrence was demonstrated.
Journal ArticleDOI
A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors.
Ephraim S. Casper,Jeffrey J. Gaynor,Steven I. Hajdu,Gordon B. Magill,C. Tan,Claudia Friedrich,Murray F. Brennan +6 more
TL;DR: A prospective randomized trial was conducted to compare the cardiotoxic and therapeutic effects of doxorubicin administered by bolus or 72‐hour continuous infusion as adjuvant chemotherapy in 82 eligible patients after resection of high‐grade soft tissue sarcoma of the extremity or superficial trunk.